{"nctId":"NCT00792909","briefTitle":"Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A","startDateStruct":{"date":"2008-12-02","type":"ACTUAL"},"conditions":["Infections, Streptococcal"],"count":172,"armGroups":[{"label":"Synflorix™ Group 1","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal conjugate vaccine GSK1024850A"]},{"label":"Synflorix™ Group 2","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal conjugate vaccine GSK1024850A"]},{"label":"Unprimed Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Pneumococcal conjugate vaccine GSK1024850A"]}],"interventions":[{"name":"Pneumococcal conjugate vaccine GSK1024850A","otherNames":[]},{"name":"Pneumococcal conjugate vaccine GSK1024850A","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female between, and including, +- 36-46 months of age at the time of vaccination.\n* For primed subjects: having completed the full vaccination course with GSK1024850A in the primary study (NCT00307034).\n* Subjects for whom the investigator believes that their parent(s)/guardian(s) can and will comply with the requirements of the protocol.\n* Written informed consent obtained from the parent(s)/guardian(s) of the subject.\n* Free of obvious health problems as established by medical history and clinical examination before entering into the study\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of the study vaccines, or planned use during the study period.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 6 months prior to vaccination.\n* For primed subjects: administration of any pneumococcal vaccine since the end of the primary study (NCT00307034).\n* For unprimed subjects: previous vaccination with any pneumococcal vaccine.\n* Administration of immunoglobulins and/or any blood products less than 6 months prior to the vaccination or planned administration during the study period.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.\n* History of reactions or allergic disease likely to be exacerbated by any component of the study vaccine.\n* Acute disease at the time of enrolment.","healthyVolunteers":true,"sex":"ALL","minimumAge":"36 Months","maximumAge":"46 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Unprimed Group","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C,19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration greater than or equal to (≥) 0.05 μg/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Unprimed Group","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C,19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Unprimed Group","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C,19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Synflorix Group 1 and Synflorix Group 2","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C,19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":null},{"groupId":"OG001","value":"1.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.97","spread":null},{"groupId":"OG001","value":"3.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.71","spread":null},{"groupId":"OG001","value":"3.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"1.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.94","spread":null},{"groupId":"OG001","value":"3.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.59","spread":null},{"groupId":"OG001","value":"3.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.91","spread":null},{"groupId":"OG001","value":"5.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.87","spread":null},{"groupId":"OG001","value":"5.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.68","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.12","spread":null},{"groupId":"OG001","value":"2.67","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Synflorix Group 1 and Synflorix Group 2","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C,19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":null},{"groupId":"OG001","value":"0.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":null},{"groupId":"OG001","value":"0.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":null},{"groupId":"OG001","value":"0.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"1.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":null},{"groupId":"OG001","value":"0.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":null},{"groupId":"OG001","value":"0.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.62","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":null},{"groupId":"OG001","value":"0.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.42","spread":null},{"groupId":"OG001","value":"1.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":null},{"groupId":"OG001","value":"0.67","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Synflorix Group 1 and Synflorix Group 2","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C,19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.06","spread":null},{"groupId":"OG001","value":"4.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.54","spread":null},{"groupId":"OG001","value":"9.97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.38","spread":null},{"groupId":"OG001","value":"7.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.18","spread":null},{"groupId":"OG001","value":"7.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.48","spread":null},{"groupId":"OG001","value":"10.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.42","spread":null},{"groupId":"OG001","value":"19.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.12","spread":null},{"groupId":"OG001","value":"22.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.28","spread":null},{"groupId":"OG001","value":"30.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.23","spread":null},{"groupId":"OG001","value":"8.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off in the Synflorix™ Group 1 and Synflorix™ Group 2","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C,19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL..","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off in the Unprimed Group;","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C,19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off in the Synflorix™ Group 1 and Synflorix™ Group 2","description":"Antibodies assessed for this outcome measure were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C,19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.2 μg/mL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off in the Unprimed Group","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C,19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.20 μg/mL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Synflorix™ Group 1 and Synflorix™ Group 2","description":"Seropositivity status was defined as opsonophacocytic activity against pneumococcal serotypes ≥ 8.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"243.9","spread":null},{"groupId":"OG001","value":"176.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"6.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2342.2","spread":null},{"groupId":"OG001","value":"2321.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"937.6","spread":null},{"groupId":"OG001","value":"1347","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null},{"groupId":"OG001","value":"9.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13247.5","spread":null},{"groupId":"OG001","value":"17732.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"181.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"991.5","spread":null},{"groupId":"OG001","value":"1221.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"292.2","spread":null},{"groupId":"OG001","value":"458.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null},{"groupId":"OG001","value":"126.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3312.9","spread":null},{"groupId":"OG001","value":"3136","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2257.8","spread":null},{"groupId":"OG001","value":"3856.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1329.1","spread":null},{"groupId":"OG001","value":"1225.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20779","spread":null},{"groupId":"OG001","value":"22461.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1581.7","spread":null},{"groupId":"OG001","value":"2013.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"307.4","spread":null},{"groupId":"OG001","value":"292.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21193.6","spread":null},{"groupId":"OG001","value":"19038.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1092.5","spread":null},{"groupId":"OG001","value":"1207.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"421.5","spread":null},{"groupId":"OG001","value":"738.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14310","spread":null},{"groupId":"OG001","value":"14670.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"375.8","spread":null},{"groupId":"OG001","value":"567.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"17.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6095.8","spread":null},{"groupId":"OG001","value":"6448.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"463.7","spread":null},{"groupId":"OG001","value":"950.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null},{"groupId":"OG001","value":"48.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2231.5","spread":null},{"groupId":"OG001","value":"5684.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1414.6","spread":null},{"groupId":"OG001","value":"1984.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"458.5","spread":null},{"groupId":"OG001","value":"465.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15688.3","spread":null},{"groupId":"OG001","value":"13812.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Unprimed Group","description":"Seropositivity status was defined as opsonophacocytic activity against pneumococcal serotypes ≥ 8.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"441.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9675.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2687.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"330","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"438.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1040.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"644.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11048.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6213.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12217.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6085.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"252.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3948.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4978.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3905.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3984.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"367.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1772.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"265.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5059","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5095.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 6A and 19A in the Synflorix™ Group 1 and Synflorix™ Group 2","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 6A and19A (ANTI-6A and19A) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":null},{"groupId":"OG001","value":"0.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":null},{"groupId":"OG001","value":"0.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":null},{"groupId":"OG001","value":"0.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.44","spread":null},{"groupId":"OG001","value":"3.76","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 6A and 19A in the Unprimed Group","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 6A and 19A (ANTI-6A and 19A) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.97","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pneumococcal Serotypes 6A and 19A Antibody Concentrations ≥ the Cut-off in the Synflorix™ Group 1 and Synflorix™ Group 2","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 6A and 19A (ANTI-6A and 19A) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pneumococcal Serotypes 6A and 19A Antibody Concentrations ≥ the Cut-off in the Unprimed Group","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 6A and 19A (ANTI-6A and 19A) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pneumococcal Serotypes 6A and 19A Antibody Concentrations ≥ the Cut-off in the Synflorix™ Group 1 and Synflorix™ Group 2;","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 6A and 19A (ANTI-6A and 19A) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.20 μg/mL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pneumococcal Serotypes 6A and 19A Antibody Concentrations ≥ 0.20 μg/mL in the Unprimed Group","description":"Antibodies assessed were those against the vaccine pneumococcal serotypes 6A and 19A (ANTI-6A and 19A) and were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (μg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.20 μg/mL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 6A and 19A in the Synflorix™ Group 1 and Synflorix™ Group 2","description":"Seropositivity status defined as opsonophacocytic activity against pneumococcal serotypes ≥ 8","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":null},{"groupId":"OG001","value":"135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null},{"groupId":"OG001","value":"81.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1639.4","spread":null},{"groupId":"OG001","value":"1267.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"35.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"799.3","spread":null},{"groupId":"OG001","value":"1871.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Titers for Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 6A and 19A in the Unprimed Group","description":"Seropositivity status defined as opsonophacocytic activity against pneumococcal serotypes ≥ 8.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"389.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"715.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"211.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"406.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Protein D (ANTI-PD) in the Synflorix™ Group 1 and Synflorix™ Group 2","description":"ANTI-PD concentrations were expressed as geometric mean concentrations (GMCs), in enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). Seropositivity status was defined as Anti-PD antibody concentrations ≥ 100 EL.U/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1438","spread":null},{"groupId":"OG001","value":"2241.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"301.6","spread":null},{"groupId":"OG001","value":"461.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1724.1","spread":null},{"groupId":"OG001","value":"2113.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Protein D (ANTI-PD) in the Unprimed Group","description":"ANTI-PD concentrations were expressed as geometric mean concentrations (GMCs), in enzyme-linked immunosorbent assay (ELISA) unit per milliliter (EL.U/mL). Seropositivity status was defined as Anti-PD antibody concentrations ≥ 100 EL.U/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"536.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"960.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With B-cells Detection in the Synflorix™ Group 1 and Synflorix™ Group 2","description":"Quantification of memory B-cells that produce antibodies against vaccine pneumococcal serotypes (PS) 6B, 18C, 19F, 23F and C-PS (Elispot assay), prior to and 7-10 days post- additional dose.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"377","spread":"459.3"},{"groupId":"OG001","value":"424.9","spread":"668.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1205.3","spread":"661.4"},{"groupId":"OG001","value":"2891.2","spread":"2274.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163.1","spread":"306.4"},{"groupId":"OG001","value":"635.4","spread":"1196.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"856.7","spread":"1211.7"},{"groupId":"OG001","value":"1626","spread":"1760.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174.2","spread":"285"},{"groupId":"OG001","value":"212.2","spread":"320.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120.1","spread":"92"},{"groupId":"OG001","value":"351.9","spread":"400.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136.1","spread":"131.8"},{"groupId":"OG001","value":"508.5","spread":"606.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153.1","spread":"216"},{"groupId":"OG001","value":"469.7","spread":"554.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"246.3","spread":"247.3"},{"groupId":"OG001","value":"751.2","spread":"790.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"167.6","spread":"92"},{"groupId":"OG001","value":"600.5","spread":"488.8"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With B-cells Detection in the Unprimed Group","description":"Quantification of memory B-cells that produce antibodies against vaccine pneumococcal serotypes (PS) 6B, 18C, 19F, 23F and C-PS (Elispot assay), prior to, and 7-10 days post-dose 1.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"246.5","spread":"310.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3014.2","spread":"4168.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"306.4","spread":"423.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"599.8","spread":"643.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"280","spread":"492.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"450","spread":"529.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159.8","spread":"220.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"432.4","spread":"478.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"751.9","spread":"463"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"789.2","spread":"751.1"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Assessed local symptoms were pain, redness and swelling. Any = occurrence of the specified solicited local symptom, regardless of intensity. Grade 3 Pain = crying when limb was moved/ spontaneously painful. Grade 3 Redness/ Swelling = Redness/ swelling at injection site greater than (\\>) 30 millimeters (mm).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number/ Percentage of Subjects With Any, Grade 3 and Related Solicited General Symptoms","description":"Assessed solicited general symptoms were drowsiness, irritability/ fussiness (Irr./Fuss.), loss of appetite (Loss Appet.) and Fever (rectal temperature ≥ 38.0 °C). Any = occurrence of the specified solicited general symptom, regardless of intensity or relationship to vaccination. Related = occurrence of the specified symptom assessed by the investigators as causally related to vaccination. Grade 3 drowsiness = drowsiness that prevented normal everyday activities. Grade 3 Irr./Fuss. = crying that could not be comforted/ prevented normal everyday activities. Grade 3 loss of appetite = not eating at all. Grade 3 fever = rectal temperature \\> 40.0°C.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number (%) of Subjects With Unsolicited Adverse Events","description":"An unsolicited AE was defined as any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any = occurrence of an unsolicited AE, regardless of intensity or relationship to vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Number (%) of Subjects With Serious Adverse Events","description":"A serious adverse event (SAE) was defined as any medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject. AE(s) considered as SAE(s) also included invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that did not result in hospitalisation, as per the medical or scientific judgement of the physician. Any = occurrence of a SAE, regardless of relationship to vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":51},"commonTop":["Pain","Redness","Swelling","Irritability","Drowsiness"]}}}